An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer

Summary

as second-line treatment in metastatic prostate cancer, the present study will investigate the efficacy of sunitinib (SUTENT) given orally at a dose of 37.5 mg continuously, for 6 cycles of 6 consecutive weeks .Patients who are still responders after 6 cycles will be treated until disease progression, pain progression, unacceptable toxicity or death due to any cause. Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individual safety and tolerability. Follow-up for up to 1 year from the last dose of sunitinib.

Timeline

Start

2008-03

Primary completion

2011-04

Completion

2011-04

Drugs

Indications